AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24862733 — intervention group
Group type: EXPERIMENTAL
Intervention: HVAD with inappropriate ICD intervention
Number of subjects: 41
Study 24862733 — intervention group
Group type: EXPERIMENTAL
Intervention: HVAD and ICD therapy
Number of subjects: 41
Study 22546751 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy
Number of subjects: 30
Study 22546751 — intervention group
Group type: COMPARATOR
Intervention: Sham osteopathy
Number of subjects: 30
Study 20622657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (Vypro II)
Number of subjects: 59
Study 20622657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (TiMesh)
Number of subjects: 59
Study 20622657 — intervention group
Group type: COMPARATOR
Intervention: Standard polypropylene mesh (Marlex)
Number of subjects: 59
Study 18299182 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 67
Study 18299182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15878732 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory signals
Number of subjects: 0
Study 15878732 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual signals
Number of subjects: 0
Study 15878732 — intervention group
Group type: EXPERIMENTAL
Intervention: Right temporal lobe resection
Number of subjects: 0
Study 15878732 — intervention group
Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 0
Study 12595837 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loaded alteplase (t-PA)
Number of subjects: 73
Study 12595837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK-tPA)
Number of subjects: 73
Study 12595837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase (n-PA)
Number of subjects: 73
Study 10228084 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigella sonnei conjugate
Number of subjects: 0
Study 10228084 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a conjugate
Number of subjects: 0
Study 10228084 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a conjugate (revaccination at 6 weeks)
Number of subjects: 0
Study 10228084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Shigella conjugates
Number of subjects: 0
Study 8739828 — intervention group
Group type: EXPERIMENTAL
Intervention: Water enema CT
Number of subjects: 121
Study 8739828 — intervention group
Group type: COMPARATOR
Intervention: Standard CT
Number of subjects: 121
Study 8100914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose allopurinol (25 mg on alternative days) plus triple immunosuppression (cyclosporin, prednisolone, azathioprine)
Number of subjects: 12
Study 8100914 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy alone (cyclosporin, prednisolone, azathioprine)
Number of subjects: 12
Study 2953224 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 15
Study 2953224 — intervention group
Group type: COMPARATOR
Intervention: captopril
Number of subjects: 15
Study 31718499 — intervention group
Group type: EXPERIMENTAL
Intervention: Greedy Rabbit (experimental group)
Number of subjects: 60
Study 31718499 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of Greedy Rabbit (control group)
Number of subjects: 60
Study 30287708 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime fill flow
Number of subjects: 2
Study 30287708 — intervention group
Group type: COMPARATOR
Intervention: Dyad flow
Number of subjects: 2
Study 26947216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth by an interprofessional team (n=451)
Number of subjects: 601
Study 26947216 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=150)
Number of subjects: 601
Study 26947216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth by an interprofessional team
Number of subjects: 601
Study 25603438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 62
Study 25603438 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution placebo
Number of subjects: 62
Study 23335738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg loading dose on day 1, followed by 100 mg daily maintenance dose)
Number of subjects: 21
Study 23335738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (150 mg daily maintenance dose for 240-kg patient)
Number of subjects: 21
Study 23335738 — intervention group
Group type: COMPARATOR
Intervention: General patient population and healthy subjects (historical data)
Number of subjects: 21
Study 20638765 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-stage teaching technique
Number of subjects: 120
Study 20638765 — intervention group
Group type: COMPARATOR
Intervention: 2-stage teaching technique
Number of subjects: 120
Study 18808338 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg of HA with AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: COMPARATOR
Intervention: 3.75 microg of HA without AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg of HA with AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: COMPARATOR
Intervention: 7.5 microg of HA without AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of HA with AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: COMPARATOR
Intervention: 15 microg of HA without AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 microg of HA with AlOH
Number of subjects: 600
Study 18808338 — intervention group
Group type: COMPARATOR
Intervention: 45 microg of HA without AlOH
Number of subjects: 600
Study 16835748 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (30 mg) alone monthly
Number of subjects: 71
Study 16835748 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (30 mg) in combination with rofecoxib (up to 50 mg bid daily)
Number of subjects: 71
Study 16835748 — intervention group
Group type: COMPARATOR
Intervention: Combined univariate group analysis
Number of subjects: 71
Study 16835748 — intervention group
Group type: COMPARATOR
Intervention: Multivariate analysis
Number of subjects: 71
Study 12515744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 144
Study 12515744 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance
Number of subjects: 144
Study 9922303 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC group (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin)
Number of subjects: 539
Study 9922303 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC group (20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Number of subjects: 539
Study 9922303 — intervention group
Group type: COMPARATOR
Intervention: AC group (1000 mg amoxicillin, 500 mg clarithromycin)
Number of subjects: 539
Study 9922303 — intervention group
Group type: COMPARATOR
Intervention: MC group (400 mg metronidazole, 250 mg clarithromycin)
Number of subjects: 539
Study 7917508 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered immediately after astemizole ingestion
Number of subjects: 21
Study 7917508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of activated charcoal (12 g) administered twice daily for 8 days
Number of subjects: 21
Study 7917508 — intervention group
Group type: COMPARATOR
Intervention: Astemizole with water only (control)
Number of subjects: 21
Study 2589274 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 96
Study 2589274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim
Number of subjects: 96
Study 2589274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 823828 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 4
Study 823828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31934821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattospes as an adjuvant to standard of care (SOC) treatment
Number of subjects: 61
Study 31934821 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment alone
Number of subjects: 61
Study 31934821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattospes as an adjuvant to SOC treatment
Number of subjects: 61
Study 30818772 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based primary care intervention with physician health-behavior counseling and four visits with a registered dietitian nutritionist over 6 months
Number of subjects: 165
Study 30818772 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based primary care intervention
Number of subjects: 165
Study 30818772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 28171877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein plus other antioxidants
Number of subjects: 100
Study 28171877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25156179 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Asc
Number of subjects: 130
Study 25156179 — intervention group
Group type: COMPARATOR
Intervention: SPS-Mg
Number of subjects: 130
Study 23485073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-band plating hemiepiphysiodesis (n = 10)
Number of subjects: 26
Study 23485073 — intervention group
Group type: COMPARATOR
Intervention: Stapling hemiepiphysiodesis (n = 10)
Number of subjects: 26
Study 21472620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electrostimulation and biofeedback device (Myo 420™)
Number of subjects: 75
Study 21472620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (FitVibe medical™)
Number of subjects: 75
Study 21472620 — intervention group
Group type: COMPARATOR
Intervention: Standardised rehabilitation therapy with pelvic floor re-education (control group)
Number of subjects: 75
Study 17881186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg plus long-acting propranolol 80mg
Number of subjects: 64
Study 17881186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg plus placebo
Number of subjects: 64
Study 17881186 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol 80mg plus placebo
Number of subjects: 64
Study 17881186 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 64
Study 16516595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level, home-based walking program for 24 weeks
Number of subjects: 99
Study 16516595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 99
Study 16516595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level, home-based walking program
Number of subjects: 99
Study 15292895 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectable, needle-free connector
Number of subjects: 243
Study 15292895 — intervention group
Group type: COMPARATOR
Intervention: 3-way stopcocks
Number of subjects: 243
Study 10890309 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (SSRI)
Number of subjects: 13
Study 9008456 — intervention group
Group type: EXPERIMENTAL
Intervention: rTOF patients with documented VT (group 1)
Number of subjects: 99
Study 9008456 — intervention group
Group type: COMPARATOR
Intervention: nontetralogy control subjects (group 4 and group 5)
Number of subjects: 99
Study 7706598 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted intake of thiamin, riboflavin, and vitamin B6 (daily diet providing no more than 55% of the Dutch RDA for these vitamins)
Number of subjects: 24
Study 7706598 — intervention group
Group type: COMPARATOR
Intervention: Regular intake of vitamins (supplemented at twice the RDA level)
Number of subjects: 24
Study 3688396 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual needling
Number of subjects: 0
Study 3688396 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (10 Hz for 5 minutes at P6 point)
Number of subjects: 0
Study 3688396 — intervention group
Group type: COMPARATOR
Intervention: Cyclizine 50 mg
Number of subjects: 0
Study 29282844 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Care Scheme (ICS)
Number of subjects: 140
Study 29282844 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 140
Study 29282844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICS and UC
Number of subjects: 140
Study 28441962 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health navigation intervention
Number of subjects: 19
Study 28441962 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application conducting ecologic momentary assessment (EMA)
Number of subjects: 19
Study 24431099 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck extension (group I)
Number of subjects: 180
Study 24431099 — intervention group
Group type: COMPARATOR
Intervention: No neck extension (group II)
Number of subjects: 180
Study 24090588 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg per day in month 1, 20 mg per day in month 2, and 20-40 mg per day in months 3-12)
Number of subjects: 84
Study 24090588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 21432860 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg once daily
Number of subjects: 30
Study 21432860 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 30
Study 21432860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study 21432860 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 30
Study 19035858 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Number of subjects: 610
Study 19035858 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240/160 mg
Number of subjects: 610
Study 19035858 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg
Number of subjects: 610
Study 19035858 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 610
Study 16985018 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention of moderate-to-vigorous aerobic exercise, 60 minutes per day, 6 days per week
Number of subjects: 202
Study 16985018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study 14689411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyruvate-fortified cardioplegia
Number of subjects: 30
Study 14689411 — intervention group
Group type: COMPARATOR
Intervention: Lactate-based cardioplegia
Number of subjects: 30
Study 10994865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast SportStirrup (braced condition)
Number of subjects: 25
Study 10994865 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced control
Number of subjects: 25
Study 8799526 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin monotherapy (500 mg single dose followed by another 500 mg on day 1 and then 250 mg twice daily for 4 days)
Number of subjects: 38
Study 8799526 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin in combination with mefloquine (500 mg single dose followed by 750 mg on day 1 and then 250 mg three times daily for one more day; Mefloquine 250 mg three times daily for the first day)
Number of subjects: 38
Study 8799526 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin monotherapy
Number of subjects: 38
Study 8799526 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin in combination with mefloquine
Number of subjects: 38
Study 1633906 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (group A) - intravenous hydrocortisone, 100 mg immediately after ultrasound-directed oocyte recovery, followed by prednisolone, 10 mg three times per day for 5 days, then 10 mg two times a day for 3 days, and 10 mg/d for 2 days.
Number of subjects: 31
Study 1633906 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoid treatment (group B).
Number of subjects: 31
Study 1633906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received luteal support with intramuscular injections of gestone 100 mg/d.
Number of subjects: 31
Study 1633906 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (group A)
Number of subjects: 31
Study 1633906 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoid treatment (group B)
Number of subjects: 31
Study 6640552 — intervention group
Group type: EXPERIMENTAL
Intervention: Human lymphoblastoid interferon at a dose of 3.0 X 10(6) units/m2 three times/week for 6 weeks, followed by maintenance treatment with interferon (3.0 X 10(6) units/m2 once/week) for those who did not progress.
Number of subjects: 19
Study 6640552 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance (no further treatment) for patients who did not progress after initial treatment.
Number of subjects: 19
Study 31739859 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakemeter (haptic stimuli device)
Number of subjects: 20
Study 31739859 — intervention group
Group type: COMPARATOR
Intervention: Actigraphy
Number of subjects: 20
Study 30397681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food consumption
Number of subjects: 300
Study 26956166 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 600 IU/day
Number of subjects: 280
Study 26956166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 3000 IU/day
Number of subjects: 280
Study 25352435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 3
Study 25352435 — intervention group
Group type: COMPARATOR
Intervention: Glycerol control
Number of subjects: 3
Study 25352435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 3
Study 21443602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg once daily for 12 or 24 weeks
Number of subjects: 32
Study 21443602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 10 mg once daily for 12 or 24 weeks
Number of subjects: 32
Study 19840748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g daily vitamin C treatment (Group II)
Number of subjects: 392
Study 19840748 — intervention group
Group type: COMPARATOR
Intervention: No vitamin C treatment (Group I)
Number of subjects: 392
Study 16490844 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 monoclonal antibody (up to 9 mg/kg every 3 weeks)
Number of subjects: 63
Study 15070003 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect patients
Number of subjects: 16
Study 15070003 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 10927048 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg)
Number of subjects: 54
Study 10927048 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin acetate (3.75 mg)
Number of subjects: 54
Study 9489383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinocort-Nasal Aerosol
Number of subjects: 79
Study 9489383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinocort-Nasal Turbuhaler
Number of subjects: 79
Study 8222654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-T 220 IUD
Number of subjects: 87
Study 8222654 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-IUD
Number of subjects: 87
Study 8222654 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 87
Study 8222654 — intervention group
Group type: COMPARATOR
Intervention: All IUDs
Number of subjects: 87
Study 8222654 — intervention group
Group type: COMPARATOR
Intervention: Bleeders vs Non-bleeders
Number of subjects: 87
Study 3530417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber
Number of subjects: 24
Study 3530417 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 24
Study 3530417 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 24
Study 3530417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial period
Number of subjects: 24
Study 3530417 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 24
Study 4646510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (emphasizing good prognosis, early mobilization, physiotherapy)
Number of subjects: 178
Study 4646510 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 178
Study 4646510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (physiotherapy)
Number of subjects: 178
Study 31461392 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU)
Number of subjects: 60
Study 31461392 — intervention group
Group type: EXPERIMENTAL
Intervention: Futurabond U (FBU)
Number of subjects: 60
Study 31461392 — intervention group
Group type: COMPARATOR
Intervention: Prime&Bond Elect (PBE)
Number of subjects: 60
Study 31461392 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (ER) strategy
Number of subjects: 60
Study 31461392 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch (SE) strategy
Number of subjects: 60
Study 28974406 — intervention group
Group type: EXPERIMENTAL
Intervention: CCH 0.58 mg plus vacuum therapy alone
Number of subjects: 30
Study 28974406 — intervention group
Group type: EXPERIMENTAL
Intervention: CCH 0.58 mg plus vacuum therapy with penile modeling
Number of subjects: 30
Study 26118143 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention using the ISHIB IMPACT cardiovascular risk reduction toolkit
Number of subjects: 54
Study 26118143 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 23745440 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical or surgical closure of ductus arteriosus (DA)
Number of subjects: 32
Study 23745440 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group B)
Number of subjects: 32
Study 22232999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 512
Study 22232999 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus pethidine
Number of subjects: 512
Study 19833276 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (0.1 mL/kg of preservative‐free 1% lidocaine pretreatment, slow rocuronium injection)
Number of subjects: 150
Study 19833276 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R (0.1 mL/kg of 0.9% NaCl pretreatment, rapid rocuronium injection)
Number of subjects: 150